Retracted on Oct 2, 2018. Do not cite it as support.
Source: Retraction Watch, via Crossref · checked Oct 30, 2026 · Read the notice
Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer
Bin Bao, Shadan Ali, Dejuan Kong and 7 more
PLoS ONE · 2011
doi:10.1371/journal.pone.0017850
Abstract
Background. The existence of cancer stem cells (CSCs) or cancer stem-like cells in a tumor mass is believed to be responsible for tumor recurrence because of their intrinsic and extrinsic drug-resistance characteristics. Therefore, targeted killing of CSCs would be a newer strategy for the prevention of tumor recurrence and/or treatment by overcoming drug-resistance. We have developed a novel synthetic compound-CDF, which showed greater bioavailability in animal tissues such as pancreas, and also induced cell growth inhibition and apoptosis, which was mediated by inactivation of NF-κB, COX-2, and VEGF in pancreatic cancer (PC) cells.
Methodology/Principal Findings. In the current study we showed, for the first time, that CDF could significantly inhibit the sphere-forming ability (pancreatospheres) of PC cells consistent with increased disintegration of pancreatospheres, which was associated with attenuation of CSC markers (CD44 and EpCAM), especially in gemcitabine-resistant (MIAPaCa-2) PC cells containing high proportion of CSCs consistent with increased miR-21 and decreased miR-200. In a xenograft mouse model of human PC, CDF treatment significantly inhibited tumor growth, which was associated with decreased NF-κB DNA binding activity, COX-2, and miR-21 expression, and increased PTEN and miR-200 expression in tumor remnants.
Conclusions/Significance. These results strongly suggest that the anti-tumor activity of CDF is associated with inhibition of CSC function via down-regulation of CSC-associated signaling pathways. Therefore, CDF could be useful for the prevention of tumor recurrence and/or treatment of PC with better treatment outcome in the future.
Full text
We don’t show the text of a retracted or withdrawn paper. The record stays, so citations to it can be checked.
References 34
- 1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
Not in our library10.3322/caac.20006
- 2.
Gaviraghi M, Tunici P, Valensin S, Rossi M, Giordano C, et al. Pancreatic cancer spheres are more than just aggregates of stem marker positive cells. Biosci Rep. 2010.
Not in our library10.1042/bsr20100018
- 3.
Hermann PC, Bhaskar S, Cioffi M, Heeschen C. Cancer stem cells in solid tumors. Semin Cancer Biol. 2010;20:77-84.
Not in our library10.1016/j.semcancer.2010.03.004
- 4.
Ischenko I, Seeliger H, Kleespies A, Angele MK, Eichhorn ME, et al. Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg. 2010;395:1-10.
Not in our library10.1007/s00423-009-0502-z
- 5.
Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol. 2008;26:2806-2812.
Not in our library10.1200/jco.2008.16.6702
- 6.
Mueller MT, Hermann PC, Heeschen C. Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci (Elite Ed). 2010;2:602-613.
Not in our library10.2741/e117
- 7.
Abas F, Lajis NH, Shaari K, Israf DA, Stanslas J, et al. A labdane diterpene glucoside from the rhizomes of Curcuma mangga. J Nat Prod. 2005;68:1090-1093.
Not in our library10.1021/np0500171
- 8.
Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631-1652.
Not in our library10.1007/s00018-008-7452-4
- 9.
Narayan S. Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting beta-catenin-mediated transactivation and cell-cell adhesion pathways. J Mol Histol. 2004;35:301-307.
Not in our library10.1023/b:hijo.0000032361.98815.bb
- 10.
Padhye S, Banerjee S, Chavan D, Pandye S, Swamy KV, et al. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res. 2009;26:2438-2445.
Not in our library10.1007/s11095-009-9955-6
- 11.
Padhye S, Yang H, Jamadar A, Cui QC, Chavan D, et al. New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res. 2009;26:1874-1880.
Not in our library10.1007/s11095-009-9900-8
- 12.
Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010;70:3606-3617.
Not in our library10.1158/0008-5472.can-09-4598
- 13.
Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65:6029-6033.
Not in our library10.1158/0008-5472.can-05-0137
- 14.
Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008;12:2171-2176.
Not in our library10.1007/s11605-008-0584-x
- 15.
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647-658.
Not in our library10.1053/j.gastro.2007.05.022
- 16.
Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243-3251.
Not in our library10.1038/sj.onc.1206390
- 17.
Sebens S, Arlt A, Schafer H. NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res. 2008;177:151-164.
Not in our library10.1007/978-3-540-71279-4_17
- 18.
Zhang Z, Rigas B. NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review). Int J Oncol. 2006;29:185-192.
Not in our library
- 19.
Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005;7:86-95.
Not in our library10.1186/bcr1021
- 20.
Sarkar FH, Li Y, Wang Z, Kong D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009;64:489-500.
Not in our library
- 21.
Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:253-260.
Not in our library10.1007/s10911-010-9173-1
- 22.
Li Y, Kong D, Wang Z, Sarkar FH. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res. 2010;27:1027-1041.
Not in our library10.1007/s11095-010-0105-y
- 23.
Sarkar FH, Li Y, Wang Z, Kong D, Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat. 2010;13:57-66.
Not in our library10.1016/j.drup.2010.02.001
- 24.
Li Y, Vandenboom TG, Wang Z, Kong D, Ali S, et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010;70:1486-1495.
Not in our library10.1158/0008-5472.can-09-2792
- 25.
Vandenboom Ii TG, Li Y, Philip PA, Sarkar FH. MicroRNA and Cancer: Tiny Molecules with Major Implications. Curr Genomics. 2008;9:97-109.
Not in our library10.2174/138920208784139555
- 26.
Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med. 2009;13:39-53.
Not in our library10.1111/j.1582-4934.2008.00556.x
- 27.
Shimosegawa T, Kume K, Satoh K. Chronic pancreatitis and pancreatic cancer: prediction and mechanism. Clin Gastroenterol Hepatol. 2009;7:S23-S28.
Not in our library10.1016/j.cgh.2009.07.042
- 28.
Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer. 2010;10:342-352.
Not in our library10.1038/nrc2842
- 29.
Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, et al. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells. 2009;27:1712-1721.
Not in our library10.1002/stem.101
- 30.
Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69:6704-6712.
Not in our library10.1158/0008-5472.can-09-1298
- 31.
Wang Z, Ahmad A, Banerjee S, Azmi A, Kong D, et al. FoxM1 is a novel target of a natural agent in pancreatic cancer. Pharm Res. 2010;27:1159-1168.
Not in our library10.1007/s11095-010-0106-x
- 32.
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
Not in our library10.1016/0065-2571(84)90007-4
- 33.
Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, et al. Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Transl Oncol. 2009;2:321-328.
Not in our library10.1593/tlo.09193
- 34.
El-Rayes BF, Ali S, Sarkar FH, Philip PA. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther. 2004;3:1421-1426.
Not in our library
Cited by papers we hold 8
- Development of asialoglycoprotein receptor directed nanoparticles for selective delivery of curcumin derivative to hepatocellular carcinoma · 2018Not checked
- Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs · 2017No notice
- Inflammaging and Cancer: A Challenge for the Mediterranean Diet · 2015No notice
- Difluorinated-Curcumin (CDF) Restores PTEN Expression in Colon Cancer Cells by Down-Regulating miR-21 · 2013No notice
- Antagonism of miR-21 Reverses Epithelial-Mesenchymal Transition and Cancer Stem Cell Phenotype through AKT/ERK1/2 Inactivation by Targeting PTEN · 2012No notice
- Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment · 2012No notice
- Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF · 2012No notice
- MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells · 2012No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.